Literature DB >> 16026138

Tinnitus retraining therapy--the experiences in Slovakia.

L Suchova1.   

Abstract

Since Mai 1999 Tinnitus Retraining Therapy (TRT) according to Jastreboff has been used in the management of 55 patients with tinnitus of various origin. Tinnitus isn't a disease, it is only a symptom. Therefore we needed to do an exact examination of the patient. We needed to apply causal therapy whenever it was possible. After six months of continuous therapy more than 50% patients reported improvement of tinnitus or it has disappeared. Concomitantly, we found hyperacusis, hypersensitivity to loud sounds. We could not assert that it was the cause or the consequence of the tinnitus. Considering these findings, it would appear TRT can be useful for extending the possibilities of tinnitus treatment. (Tab. 5, Fig. 1, Ref. 13.)

Entities:  

Mesh:

Year:  2005        PMID: 16026138

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  3 in total

Review 1.  Clinical Interventions for Hyperacusis in Adults: A Scoping Review to Assess the Current Position and Determine Priorities for Research.

Authors:  Kathryn Fackrell; Iskra Potgieter; Giriraj S Shekhawat; David M Baguley; Magdalena Sereda; Derek J Hoare
Journal:  Biomed Res Int       Date:  2017-10-09       Impact factor: 3.411

2.  The effect of tinnitus retraining therapy on chronic tinnitus: A controlled trial.

Authors:  Carol A Bauer; Jennifer L Berry; Thomas J Brozoski
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-05-28

3.  Identifying and prioritising unanswered research questions for people with hyperacusis: James Lind Alliance Hyperacusis Priority Setting Partnership.

Authors:  Kathryn Fackrell; Linda Stratmann; Veronica Kennedy; Carol MacDonald; Hilary Hodgson; Nic Wray; Carolyn Farrell; Mike Meadows; Jacqueline Sheldrake; Peter Byrom; David M Baguley; Rosie Kentish; Sarah Chapman; Josephine Marriage; John Phillips; Tracey Pollard; Helen Henshaw; Toto A Gronlund; Derek J Hoare
Journal:  BMJ Open       Date:  2019-11-21       Impact factor: 3.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.